Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG , 88397 Biberach an der Riss, Germany.
Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd. , Kobe 650-0046, Japan.
Mol Pharm. 2017 Oct 2;14(10):3436-3447. doi: 10.1021/acs.molpharmaceut.7b00449. Epub 2017 Sep 19.
Transporters at the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) play a pivotal role as gatekeepers for efflux or uptake of endogenous and exogenous molecules. The protein expression of a number of them has already been determined in the brains of rodents, nonhuman primates, and humans using quantitative targeted absolute proteomics (QTAP). The dog is an important animal model for drug discovery and development, especially for safety evaluations. The purpose of the present study was to clarify the relevance of the transporter protein expression for drug distribution in the dog brain and CSF. We used QTAP to examine the protein expression of 17 selected transporters and receptors at the dog BBB and BCSFB. For the first time, we directly linked the expression of two efflux transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), to regional brain and CSF distribution using specific substrates. Two cocktails, each containing one P-gp substrate (quinidine or apafant) and one BCRP substrate (dantrolene or daidzein) were infused intravenously prior to collection of the brain. Transporter expression varied only slightly between the capillaries of different brain regions and did not result in region-specific distribution of the investigated substrates. There were, however, distinct differences between brain capillaries and choroid plexus. Largest differences were observed for BCRP and P-gp: both were highly expressed in brain capillaries, but no BCRP and only low amounts of P-gp were detected in the choroid plexus. K and K of both P-gp substrates were indicative of drug efflux. Also, K for the BCRP substrates was low. In contrast, K for both BCRP substrates was close to unity, resulting in K/K ratios of 7 and 8, respectively. We conclude that the drug transporter expression profiles differ between the BBB and BCSFB in dogs, that there are species differences in the expression profiles, and that CSF is not a suitable surrogate for unbound brain concentrations of BCRP substrates in dogs.
血脑屏障 (BBB) 和血脑脊液屏障 (BCSFB) 中的转运蛋白作为内源性和外源性分子流出或摄取的守门员起着至关重要的作用。使用定量靶向绝对蛋白质组学 (QTAP),已经在啮齿动物、非人灵长类动物和人类的大脑中确定了它们中的许多蛋白质的表达。狗是药物发现和开发的重要动物模型,特别是用于安全性评估。本研究的目的是阐明转运蛋白表达与狗脑和 CSF 中药物分布的相关性。我们使用 QTAP 检查了 17 种选定的转运体和受体在狗 BBB 和 BCSFB 的蛋白表达。我们首次使用特定的底物将两种外排转运蛋白 P-糖蛋白 (P-gp) 和乳腺癌耐药蛋白 (BCRP) 的表达与脑和 CSF 的区域分布直接联系起来。在收集大脑之前,静脉内输注两种包含一种 P-gp 底物 (quinidine 或 apafant) 和一种 BCRP 底物 (dantrolene 或 daidzein) 的鸡尾酒。转运体表达在不同脑区的毛细血管之间仅略有差异,不会导致研究底物的区域特异性分布。然而,脑毛细血管和脉络丛之间存在明显差异。最大的差异出现在 BCRP 和 P-gp 中:两者在脑毛细血管中高度表达,但在脉络丛中没有 BCRP 且仅检测到少量 P-gp。两种 P-gp 底物的 K 和 K 均表明药物外排。此外,BCRP 底物的 K 也较低。相比之下,两种 BCRP 底物的 K 接近 1,导致 K/K 比值分别为 7 和 8。我们得出结论,狗的 BBB 和 BCSFB 之间的药物转运体表达谱不同,表达谱存在种间差异,并且 CSF 不是狗中 BCRP 底物的未结合脑浓度的合适替代物。